Middle East & Africa Gastroesophageal Reflux Disease Therapeutics Market Size & Outlook
Middle East & Africa gastroesophageal reflux disease therapeutics market, 2018-2030 (US$M)
Related Markets
MEA gastroesophageal reflux disease therapeutics market highlights
- The MEA gastroesophageal reflux disease therapeutics market generated a revenue of USD 207.6 million in 2023.
- The market is expected to grow at a CAGR of 2.4% from 2024 to 2030.
- In terms of segment, antacids was the largest revenue generating drug type in 2023.
- H2 Receptor Blockers is the most lucrative drug type segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 207.6 million |
| Market revenue in 2030 | USD 245.0 million |
| Growth rate | 2.4% (CAGR from 2023 to 2030) |
| Largest segment | Antacids |
| Fastest growing segment | H2 Receptor Blockers |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), Pro-kinetic agents |
| Key market players worldwide | AstraZeneca PLC, Eisai Co Ltd, GSK PLC, Takeda Pharmaceutical Co Ltd, Ironwood Pharmaceuticals Inc Class A, Johnson & Johnson, Phathom Pharmaceuticals Inc Ordinary shares |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.9% of the global gastroesophageal reflux disease therapeutics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,607.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gastroesophageal Reflux Disease Therapeutics Market Scope
Gastroesophageal Reflux Disease Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa gastroesophageal reflux disease therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastroesophageal reflux disease therapeutics market will help companies and investors design strategic landscapes.
Antacids was the largest segment with a revenue share of 56.6% in 2023. Horizon Databook has segmented the Middle East & Africa gastroesophageal reflux disease therapeutics market based on antacids, h2 receptor blockers, proton pump inhibitors (ppis), pro-kinetic agents covering the revenue growth of each sub-segment from 2018 to 2030.
The prevalence of GERD in Middle East in 2013 reportedly varies between 8.7% and 33.1%, which changes geographically. In addition, unavailability of proper study data limits the understanding of GERD in the region. The prevalence of GERD in Africa is also increasing since the past few years.
Reasons to subscribe to Middle East & Africa gastroesophageal reflux disease therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa gastroesophageal reflux disease therapeutics market databook
-
Our clientele includes a mix of gastroesophageal reflux disease therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa gastroesophageal reflux disease therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa gastroesophageal reflux disease therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA gastroesophageal reflux disease therapeutics market outlook size, by country, 2018-2030 (US$M)
Middle East & Africa Gastroesophageal Reflux Disease Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
